UK public healthcare tests psilocybin against true placebo

Psiconáutica Editorial Team · September 2, 2026

Thirty people living with depression that had failed to respond to previous treatments received a single 25 mg dose of psilocybin, supported by psychological care before and after. Another thirty underwent the exact same protocol, but received a capsule with no active ingredient. At six weeks, half of the first group showed meaningful improvement; in the second, virtually no one did. These are the findings of the PsiDeR trial, the first psilocybin study funded by the British public research system rather than a commercial pharmaceutical firm.

A placebo that truly does nothing

Most clinical trials involving psilocybin compare the compound to niacin or an active microdose that produces mild physiological sensations, attempting to prevent participants from guessing their assignment. The team led by James Rucker, a consultant psychiatrist at King’s College London and the South London and Maudsley NHS Foundation Trust, took the opposite route: a genuinely inert placebo. Scientifically, it is a more rigorous approach, though far harder to keep blinded, since anyone receiving psilocybin quickly realizes something is happening. The authors acknowledge this frankly in the paper: functional unblinding may have inflated part of the observed effect. Funded by the National Institute for Health and Care Research (NIHR), the study also served as a feasibility test: evaluating whether a public hospital could deliver psilocybin under rigorous trial standards—a feat previously underwritten almost exclusively by commercial ventures like Compass Pathways.

The trial numbers

At three weeks, 43% of the psilocybin group met criteria for clinical response (a reduction of at least 50% on the MADRS depression scale), compared to 3% in the placebo group; full remission reached 40% versus 3%. By week six, the response rate climbed to 50% in the psilocybin group while placebo remained flat at 3%. The mean difference on the MADRS scale was 10.4 points at three weeks and nearly 13 points at six weeks, reflecting what statisticians classify as very large effect sizes. Regarding safety, researchers recorded 164 mild adverse events in the psilocybin group compared to 123 in the placebo arm—most resolving within the study period—and four serious adverse events (three with psilocybin, one with placebo). Operations ran smoothly: 83% of screened candidates were eligible, 100% assigned to psilocybin attended their dosing session, and 98% completed follow-up assessments.

What this means

With only 60 participants and six weeks of follow-up, declaring psilocybin an established treatment would be premature; this is a Phase 2 trial designed, in part, to prove that the public healthcare system can execute such protocols, not merely to quantify an antidepressant effect. Nor does it resolve the fundamental methodological challenge shadowing all clinical research into psychedelics: truly blinding someone experiencing an altered state of consciousness is nearly impossible, meaning expectancy may account for a portion of the gains. That said, having the NIHR—rather than a corporation with a commercial stake—fund the work fundamentally shifts the quality of evidence being generated. It lays the groundwork for psilocybin therapy to potentially enter the NHS without depending on a pharmaceutical company’s pricing model.

Fuente

• King’s College London. Promising results from first publicly funded UK randomised trial of psilocybin for depression. King’s College London News, August 6, 2026.

Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.